As the highest medical research institution and the highest medical education institution in China, Peking Union Medical College has always taken the development of medical science and technology education in China and the maintenance of people's health as its own responsibility since its establishment, and has made important contributions to the development of China's medical and health undertakings. Today's Concord has a bright lineup of stars and talents. The school has 5 academicians of the Chinese Academy of Sciences and 18 academicians of the Chinese Academy of Engineering. In this issue of push, let's enjoy these big people's style together!
< h1 class="pgc-h-arrow-right" data-track="3" > academician of the Chinese Academy of Sciences</h1>
Qiang Boqin (1939.09- ) is a biochemist and molecular biologist from Shanghai. He is a researcher at the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, a professor and doctoral supervisor of the Department of Biochemistry and Molecular Biology of Peking Union Medical College. He was the Vice President of the Chinese Academy of Medical Sciences and the Vice President of Peking Union Medical College. In 1991, he was co-elected as an academician of the Chinese Academy of Sciences.
In the 1960s, he was mainly engaged in research on chemical structures such as tRNA, and since the 1980s, he has undertaken national "research" and "863 program" projects, carried out genetic engineering research such as nucleic acid tool enzymes, cytokines and malaria antigens, and has been mainly engaged in human genome sequencing and function research since the early 1990s. Research on the Genetic Structure of Several Loci of the Chinese Genome", 973 Project "Establishment of Disease Genomics Theory and Technology System". Participated in the organization and coordination of the 1% mission of the International Human Genome Sequencing Program in China.
Shen Yan (1956.10- ), molecular geneticist. He has made important contributions in the fields of single-gene genetic diseases and molecular mechanisms of multi-gene complex diseases. He is currently the vice chairman of the Chinese Association for Science and Technology, a researcher and doctoral supervisor of the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. He successively served as the dean of the Basic College of Peking Union Medical College and the director of the Institute of Basic Medical Research. In 2003, he was elected as an academician of the Chinese Academy of Sciences, in 2005 he was awarded the He Liang He Li Science and Technology Progress Award, and in 2007 he was awarded the National May Day Labor Medal.
He is mainly engaged in gene recognition, DNA diagnosis and molecular mechanism research of human genetic diseases. In the research of single-gene genetic diseases, through cooperation with clinical units, it has been found for the first time in the world that DSPP gene mutations lead to hereditary milky dentin, CACNA1H gene mutations are related to the incidence of absent epilepsy in children, SCN9A gene mutations lead to erythematous limb pain, and CRYGS gene mutations lead to simple congenital cataracts.
Zhao Yupei (1954.07- ), Surgeon. People from Changchun, Jilin Province. He received a master's degree from Peking Union Medical College in 1987. He is currently a professor and president of Peking Union Medical College Hospital and the vice chairman of the China Association for Science and Technology. In 2011, he was elected as an academician of the Chinese Academy of Sciences.
Systematic and pioneering work has been carried out in clinical and basic research on the early diagnosis and comprehensive treatment of pancreatic cancer. Take the lead in formulating the diagnosis and treatment process of pancreatic cancer in China and national industry standards. The concept of high-risk population of pancreatic cancer is proposed, and through the establishment of multidisciplinary collaborative consultation centers, rapid diagnosis and treatment green channels, preoperative resectability assessment system, standardizing the scope of surgical resection, and establishing transsoclerogastomy, etc., the diagnosis time is shortened, more patients are won surgical opportunities, the quality of life is improved, and the comprehensive indicators such as surgical resection rate, postoperative complication rate and patient survival time of Peking Union Medical College Hospital are significantly better than the international level of the same period; the surgical treatment of insulinomas in the world's largest group of single-center insulinomas is reported. The first laparoscopic insulinoma resection in China was performed. His research achievements have won many awards such as the second prize of the National Science and Technology Progress Award.
He jie (1960.08- ), thoracic specialist, born in Jilin Province. Chairman of Thoracic and Cardiovascular Surgery Branch of Chinese Medical Association, Chairman of Asian Association of Thoracic Surgeons, Vice Chairman of China Anti-Cancer Association, Vice President of Chinese Hospital Association, Vice President of Chinese Medical Doctor Association. In 2013, he was elected as an academician of the Chinese Academy of Sciences.
He has been engaged in the clinical work of thoracic surgery for a long time, leading the development of thoracic surgery, committed to the surgical clinical diagnosis and treatment and research of lung cancer and esophageal cancer, and has achieved remarkable results in clinical, basic and translational medicine research. Promote national tumor prevention and control work and standardized diagnosis and treatment of tumors and quality control. He has presided over a number of national key research and development programs, high-tech research and development programs, scientific and technological support plans, health industry special projects and other national major projects, and won the first prize of national scientific and technological progress in the "research and application promotion of key technologies for standardized treatment of esophageal cancer" led by the first person to complete it.
Gu Dongfeng (1958.11-), Preventive Cardiology, born in Jiangsu. He received his M.S. and Ph.D. degrees from Peking Union Medical College in 1986 and 2007, respectively. In 2017, he was elected as an academician of the Chinese Academy of Sciences. He is currently the deputy director of the National Center for Cardiovascular Diseases and the vice president of Fuwai Hospital of the Chinese Academy of Medical Sciences.
He is mainly engaged in epidemiology, population prevention and control and genetic etiology research of chronic diseases such as cardiovascular diseases. Through long-term prospective cohorts and other studies, it reveals the incidence and epidemic trend of cardiovascular diseases and important pathogenesis factors in China, creates a risk prediction model for cerebrovascular diseases in The Chinese people, develops the ideal health indicators of the Chinese cardiovascular system, proposes appropriate prevention and treatment strategies and measures, and takes the lead in formulating risk assessment and management guidelines for cardiovascular diseases in China, which are applied to the early prevention of hypertension and the prevention and treatment of cardiovascular diseases. Projects such as "Research on the Development Trend and Prevention and Treatment Strategy of Cardiovascular Diseases in China" led by him won two second prizes for national scientific and technological progress. Authorized by 16 invention patents in China.
Budnian (1938.10.27- ) immunologist. He graduated from Beijing Medical University in 1967 and received his Ph.D. from Hokkaido University in Japan in 1982. Former President of the Chinese Academy of Medical Sciences and former President and Professor of Peking Union Medical College. In 1994, he was elected as an academician of the Chinese Academy of Engineering.
For the first time, anti-thymic antibodies were discovered, thus revealing the causes of low immune function in hypertensive rats; using immune reconstruction methods such as thymus transplantation, evidence related to immunity and hypertension was proposed for the first time in the world; combined with the actual situation in China, the research on the mechanism and prevention and treatment of cancer metastasis was carried out, and 5 animal models with high metastasis and stable high metastatic cell lines were established in China. At the same time, a series of achievements have been made in the induction of endogenous interleukin-2, the application of allopotentional LAK cells, the principle of LAK cell killing, and the clinical treatment of LAK cells.
Liu Yuqing (1923.03.14- ) Radiology-medical imaging expert. Tianjin Ninghe people. He graduated from the former National Shenyang Medical College with a bachelor's degree in 1948 and graduated from Peking Union Medical College in 1951. The main founder of cardiovascular radiography in China. In 1994, he was elected as an academician of the Chinese Academy of Engineering.
Since the 1950s, he has made outstanding achievements in the radiodiagnostic research of bronchography, lung abscess, esophageal cancer, cardiovascular angiography, cardiomyopathy, aortic disease, congenital heart disease, pulmonary heart disease, and coronary heart disease, as well as in recent years, and in recent years, he has made outstanding achievements in the application of new technologies such as digital subtraction angiography and cardiac macrovascular magnetic resonance imaging, and belongs to the leading position in China. In the field of cardiovascular radiology-imaging research, he has won 8 scientific and technological achievement awards, of which the research of aorticitis is at the international advanced level. It has made important contributions to promoting the development of radiology and medical imaging in China.
Xiao Peigen (1932.02.02- ) is an expert in medicinal plants and traditional Chinese medicine resources. A native of Shanghai. Honorary Director of the Institute of Medicinal Plants, Chinese Academy of Medical Sciences, Researcher, Doctoral Supervisor. He was a consultant and director of the Collaborative Center of Traditional Medicine of the World Health Organization, the president of the International Association of Traditional Medicine, and an internationally renowned traditional pharmacist. In 1994, he was elected as an academician of the Chinese Academy of Engineering.
Academician Xiao Peigen is the main founder and academic leader of China's medicinal plant industry, and has created a multidisciplinary penetration of "medicinal plant affinity" including plants, chemistry, efficacy and computer technology, and has become an original scientific research achievement with independent intellectual property rights in China. The Institute of Medicinal Plants of the Chinese Academy of Medical Sciences was established and served as the first director, and the three-level development strategy theory based on the development of raw materials, pharmaceutical preparations and new drugs was put forward and applied to practice, achieving significant social and economic benefits, and laying a theoretical foundation for the development and utilization of pharmaceutical resources in China.
Zhu Xiaodong (1932.09.21- ) Cardiovascular Surgery Specialist. A native of Kaifeng, Henan Province. He graduated from Harbin Medical University in 1956. He graduated from the Chinese Academy of Medical Sciences in 1965 with a master's degree. Chief Physician of the Chinese Academy of Medical Sciences, former President of Fuwai Hospital, Director of the Institute of Cardiovascular Diseases. In 1996, he was elected as an academician of the Chinese Academy of Engineering.
The main scientific and technological achievements and contributions include: 1) more than 50 years of clinical practice in cardiology surgery, comprehensive development of various types of cardiac and macrovascular surgery and participation in the construction of the national cardiac surgery technology collaboration network; 2) early engaged in cardiac catheterization and hemodynamic research; 3) engaged in the research of artificial heart valves and ventricular assist devices. His representative achievements are the development and promotion of biological heart valves and the National Invention Award. In 2004 and 2005, he was President of the 14th and 15th International Conferences of the World Association of Cardiothoracic Surgeons.
Depei Liu (1950.05.04- ) is a medical molecular biologist. A native of Funan, Anhui. He graduated from Peking Union Medical College in 1986 with a Ph.D. in Biochemistry and Molecular Biology. He was the Vice President of the Chinese Academy of Engineering, the President of the Chinese Academy of Medical Sciences, and the President of Peking Union Medical College. In 1996, he was elected as an academician of the Chinese Academy of Engineering. In 2008, he was elected a fellow of the American Academy of Medical Sciences (NAM) and the Third World Academy of Sciences (TWAS). In 2016, he was elected co-chair of the International Academy of Medical Sciences (IAPH) organization (re-elected in 2019).
Comrade Liu Depei is mainly engaged in gene expression regulation, gene therapy and cardiovascular disease pathogenesis research. He has successively undertaken the National Science Foundation for Outstanding Young People, the National Natural Science Foundation of China, the National Natural Science Foundation of China, the National 863 Key Project, etc., the academic leader of the "Excellent Innovation Group" of the National Natural Science Foundation of China, and the chief scientist of the Cardiovascular 973 Project. So far, he has published more than 200 papers and has been cited more than 5,000 times.
Wang Linfang (1929.11.03- ), biochemist and molecular biologist, born in Harbin. Professor and doctoral supervisor of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. In 1959, he graduated from the Department of Biochemistry of Peking Union Medical College. He is currently the Honorary Director of the State Key Laboratory of Molecular Biology in Medicine and the Deputy Director of the Academic Committee of the Institute of Basic Medical Sciences. In 1997, he was elected as an academician of the Chinese Academy of Engineering.
He has long been committed to the study of the relationship between protein structure and antigenicity. In the 1960s, he participated in the leadership of the creation of two kinds of animal blood Qing Dynasty plasma needed for combat readiness; in the 1970s, he carried out the exploration of the molecular basis of acupuncture anesthesia; After 1978, he organized and led reproductive biology research, conducted systematic research on the purification, structural function and gene cloning and expression of sperm proteins, and took the lead in carrying out gene expression research on sperm protein genes at the level of transcription and translation in China, which won the first prize of science and technology progress of the Ministry of Health in 1993 and the second prize of the National Natural Science Award in 1995.
Zhen Yongsu (1931.11.10- ) is an expert in microbiology and biotechnology pharmacy and tumor pharmacology. A native of Kaiping City, Guangdong Province. He is currently the director of the Oncology Research Office of the Institute of Pharmaceutical Biotechnology of the Chinese Academy of Medical Sciences and Peking Union Medical College, a researcher, a professor, and a doctoral supervisor. In 1997, he was elected as an academician of the Chinese Academy of Engineering.
Engaged in drug research of microbial sources, presided over the development of anti-tumor antibiotics such as Pingyang mycin, Zhengguangmycin, Brilliant Mycin, Boanmycin, etc., of which Pingyang mycin was included in the Pharmacopoeia of the People's Republic of China and listed as a national essential drug. Engaged in the research of anti-tumor drug screening methods, created the "spermatocellar method" and applied it to drug screening, and discovered a new anti-tumor antibiotic lidamycin; and developed anti-tumor biochemical regulatory drugs with "nucleoside transport" as the target. Engaged in the research of anti-tumor antibody drugs, the development of chemical conjugates between antibodies and drugs and genetically engineered fusion proteins, the establishment of a highly efficient and miniaturized antibody conjugated drug preparation technology platform, the construction of antibody drugs with dual-targeting functions and ligand oligopeptide drugs. He has won 1 second prize of the National Invention Award and 2 first prizes of the Ministerial Science and Technology Progress Award. In 2001, he was awarded the Ho Leung Ho Lee Science and Technology Progress Award.
Yu Dequan (1932.10.22- ) is an expert in natural medicinal chemistry. He graduated from Beijing Medical College in 1956. He is currently a researcher at the Institute of Materia Medica of the Chinese Academy of Medical Sciences and Peking Union Medical College, and a doctoral supervisor. In 1999, he was elected as an academician of the Chinese Academy of Engineering.
Engaged in natural medicinal chemistry and new drug creation research, completed nearly 100 kinds of Chinese herbal chemical composition research, discovered hundreds of new compounds and determined their chemical structure. For the first time, peroxide bonds were found to be effective groups for antimalarials. In China, it is the first to use modern 2DNMR technology to study the chemical structure of natural products and promote it. Participated in presiding over and completed the national research project "artificial musk" research, put forward the "artificial musk" formula principle, designed the formula composition scheme, created the main active ingredient in the "artificial musk" aromatic hormone, and solved the relevant technical problems in the artificial musk chemistry, formula design, production process and quality control, and production process.
Sun Yan (1929.02.01- ) clinical oncologist. Hebei Leting people. He graduated from Peking Union Medical College in 1956 with a doctorate. He is currently the director of the National New Drug (Anti-Tumor) Clinical Research Center at the National Cancer Center (NCC). He is also the Vice Chairman of the China Cancer Foundation, and the Honorary Chairman of the Asian Society of Clinical Oncology and the Chinese Society of Clinical Oncology. He has served on the WHO Cancer Advisory Committee and the UICC Education Committee, and has a certain reputation internationally. One of the founders and pioneers of medical oncology treatment in China. In 1999, he was elected as an academician of the Chinese Academy of Engineering.
For more than half a century, he has made outstanding contributions to the development of professions and disciplines, the promotion of comprehensive treatment, the development of new anti-tumor drugs and the research of integrated traditional Chinese and Western medicine and the cultivation of professional talents. For the development of Innovative Drugs in China, he won the 1978 National Science Conference Award (N-Formyl Lyseurolomacin), the First Prize of the National Science and Technology Progress Award (Targeting the New Drug Extinib), the Second Prize twice (Cancer Targeted Therapy and the New Drug Oliverhene Injection), the Invention Award 1 time (Recombinant Human Vascular Endothelial Inhibitin) and a number of provincial and ministerial awards.
Gao Runlin (1941.05.04- ) cardiovascular specialist. A native of Tangshan, Hebei Province. He graduated from Beijing Medical University in 1965 and received his master's degree from Peking Union Medical College in 1981. He was the president of the Chinese Academy of Medical Sciences, the Institute of Cardiovascular Diseases, and the Fuwai Cardiovascular Disease Hospital, and was elected as an academician of the Chinese Academy of Engineering in 1999.
He has long been engaged in clinical and scientific research of cardiovascular diseases, is one of the pioneers of interventional cardiology in China, and has taken the lead in carrying out emergency interventional treatment and a number of new technologies for acute myocardial infarction and complicated cardiogenic shock in China, contributing to the popularization, promotion and standardization of interventional treatment for coronary heart disease in China and the expansion of China's influence in the international interventional community. He has also made remarkable achievements in the clinical treatment of coronary heart disease, pathophysiology and treatment of angina pectoris, myocardial infarction reperfusion therapy, clinical trials of new drugs and epidemiological research of cardiovascular diseases, and has won 3 second prizes of the National Science and Technology Progress Award and 6 provincial (ministerial) awards.
Cheng Shujun (1939.12.02- ) graduated from the Medical Department of Beijing Medical College in 1962 and graduated from the Department of Pathology of Peking Union Medical College in 1965 with a master's degree in experimental oncology. He was the deputy president of the Institute of Oncology/Cancer Hospital of the Chinese Academy of Medical Sciences, the vice chairman of the Chinese Anti-Cancer Association, the chief scientist of the "973" tumor project of the National Key Basic Research Development Plan, and was elected as an academician of the Chinese Academy of Engineering in 1999.
Invented green tea catechins to treat genital warts, this original invention has been awarded an international patent, in 2006 by the UNITED States FDA approved for marketing. This is the first time in more than 50 years that a complex ingredient plant drug approved in the United States is marketed as a prescription drug. In 2009, he was awarded the Ho Leung Ho Lee Medical Pharmacy Award.
Cao Xuetao, (1964.07.19- ) from Jinan, Shandong Province, is an expert in immunology. He is currently the deputy secretary of the party committee and president of Nankai University. He is also the chairman of the Chinese Society of Biomedical Engineering, the chairman of the Life Science Consortium of the Chinese Association for Science and Technology, the secretary general of the Alliance of Immunological Societies in Asia-Pacific, the secretary-general of the Chinese Society of Immunology, and the director of the State Key Laboratory of Medical Immunology. In 2005, he was elected as an academician of the Chinese Academy of Engineering.
He is mainly engaged in the basic research of natural immunity and inflammation, and the application of tumor immunotherapy. He has published more than 230 SCI papers in Cell, Nature, Science, etc. as a corresponding author, and has cited more than 10,000 times. He has won 1 second prize of national natural science (2003), 2 first prizes of Chinese medical science and technology awards, 2 first prizes of scientific and technological progress in the army and Shanghai, 4 first prizes of shanghai natural sciences, 16 national invention patents, and 2 national class II new drug certificates. He has won the Guanghua Engineering Science and Technology Award of the Chinese Academy of Engineering (2012), the Chen Jiageng Life Science Award of the Chinese Academy of Sciences (2016), the Jiang Scholar Achievement Award of the Ministry of Education, and the Young Scientist Award of China.
Qiu Guixing (1942.03.13- ) Orthopedic scientist. A native of Wuxi, Jiangsu Province. He graduated from Peking Union Medical College in 1968 (eight years). Professor of Peking Union Medical College Hospital, doctoral supervisor, expert receiving special government allowances. In 2007, he was elected as an academician of the Chinese Academy of Engineering.
He has been engaged in orthopedic clinical, scientific research and teaching for a long time, especially in the field of spinal deformities: the international classification of idiopathic scoliosis - "Concord Classification" was proposed internationally, and published in the international authoritative journal of spine surgery "Spine"; in addition, the most important pathogenic gene of congenital scoliosis patients was found for the first time in the world, and the world's top medical journal "New England Medical Journal" (impact factor = 54.42 points) was originally published in 2015 (Original Article) was published in the form of an independent intellectual property rights of the spinal internal fixation system. He has won 2 second prizes of national scientific and technological progress and 9 authorized patents (2 inventions). He has published more than 600 books and edited 38 monographs such as "Orthopedic Surgery".
Lang Jinghe (1940.4.18- ) is a native of Jilin and graduated from Bethune Medical University in 1964. After that, he worked in Peking Union Medical College Hospital of Peking Union Medical College of Chinese Academy of Medical Sciences. Director, Professor and Doctoral Supervisor of the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital. In 2011, he was elected as an academician of the Chinese Academy of Engineering.
The pathogenesis of endometriosis is studied, and the "in-place endometrial determinism" and "source treatment theory" are proposed; the research on lymphatic metastasis of ovarian cancer and the diagnosis and treatment of gynecological endoscopic surgery, cervical cancer prevention and treatment, diagnosis and treatment of pelvic floor disorders in women and basic research have made outstanding contributions. He has won 8 National Science and Technology Progress Awards, Ministry of Health, Ministry of Education, China Science and Technology Progress Awards and Beijing Science and Technology Awards, and won the 2004 He Liang He Li Science and Technology Progress Award, the 2005 Beijing Model Worker, the National May Day Labor Medal and the title of National Famous Teacher in Colleges and Universities.
Chen Wang (1962.08- ) Respiratory and Critical Care Medicine Specialist. He graduated from the Medical Department of Capital Medical University in 1985 and obtained his Doctor of Medicine degree from the same university in 1991. Member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference, Vice President of the Chinese Academy of Engineering, President of the Chinese Academy of Medical Sciences and Peking Union Medical College. In 2013, he was elected as an academician of the Chinese Academy of Engineering.
It is one of the main leaders and promoters in the fields of respiratory failure and respiratory support technology, pulmonary embolism and pulmonary hypertension, emerging respiratory infectious diseases, chronic obstructive pulmonary disease, and tobacco disease in China. He has made a number of innovations such as sequential mechanical ventilation, pulmonary embolism reduction thrombolytic therapy, and confirmed the efficacy of traditional Chinese medicine on influenza and entered international guidelines to guide the improvement of clinical practice. He has won 1 special prize, 1 first prize and 3 second prizes of the National Science and Technology Progress Award, and won many awards such as the He Liang He Li Science and Technology Progress Award and the World Health Organization Tobacco Control Outstanding Contribution Award.
Lin Dongxin (1955.10.24- ) Tumor genetics and molecular epidemiologist. A native of Fuzhou City, Fujian Province, he is currently the director of the Etiology and Cancer Lesion Research Laboratory of the Cancer Hospital of the Chinese Academy of Medical Sciences, and the chairman of the Oncology Professional Committee of the Chinese Anti-Cancer Association. In 2013, he was elected as an academician of the Chinese Academy of Engineering.
His research interests include the molecular mechanisms of malignancy and their genetic susceptibility. His main academic contributions are to reveal the genetic susceptibility genes of important tumors such as esophageal cancer, pancreatic cancer and lung cancer in China, the interaction between susceptibility genes and the environment, and the influence of genetic variations on the efficacy and prognosis of tumor radiotherapy and chemotherapy. He has published more than 260 scientific papers in journals such as Nature Genetics, has been cited more than 14,000 times, and has an H-index of 68. His research achievements have won the second prize of the National Natural Science Award, the first prize of the National Science and Technology Progress Award, the second prize of the National Science and Technology Progress Award, and the first prize of the Natural Science Award of the Ministry of Education.
Hu Shengshou (1957.04.19- ) Cardiovascular Surgeon Specialist. A native of Wuhan, Hubei Province. In 1989, he obtained a master's degree in surgery from Peking Union Medical College (now Peking Union Medical College). He is currently the director of the National Cardiovascular Disease Center, the president of Fuwai Hospital of the Chinese Academy of Medical Sciences, and the director of the State Key Laboratory of Cardiovascular Diseases. In 2013, he was elected as an academician of the Chinese Academy of Engineering.
Professor Hu Shengshou has been engaged in clinical, teaching and scientific research in cardiovascular surgery for a long time, established a series of minimally invasive treatment technologies for coronary heart disease surgery in China, opened up a new model of "composite technology" for the treatment of cardiovascular diseases, created the first key laboratory of cardiovascular regenerative medicine in China, and achieved a series of research results from cardiomyocyte regeneration to heart transplantation and artificial heart development; and founded the aortic-pulmonary artery "double root transfer surgery (DRT)", which significantly improved the international influence of complex congenital heart disease treatment in China. He has won 3 second prizes of national scientific and technological progress, 3 first prizes of provincial and ministerial scientific and technological progress, and 5 second prizes.
Zhang Xue (1964.07.15-), male, medical geneticist, from Zhaozhou County, Daqing City, Heilongjiang Province. He is currently the president of Harbin Medical University, the director of the Department of Medical Genetics of the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences - Peking Union Medical College College (long-term professor), the chairman of the Expert Committee on Rare Disease Diagnosis and Treatment and Protection of the National Health Commission, the president of the Medical Genetics Physician Branch of the Chinese Medical Doctor Association, and the former vice president of the Chinese Academy of Medical Sciences - Peking Union Medical College. In 2019, he was elected as an academician of the Chinese Academy of Engineering.
Mainly engaged in the research of pathogenic genes of rare genetic diseases, he found the pathogenic GENES of single gene diseases such as familial abnormal acne and the pathogenic DNA rearrangement of genomic diseases such as congenital systemic hirsutism, revealing two new mechanisms of gene inhibition upstream open reading frame (uORF) pathogenic mutations and palindrome structure-mediated chromosomal insertion. Pathogenic mutation profiles and genetic diagnosis studies of a variety of rare genetic diseases have been systematically carried out. In 2014, the project "New Discoveries of Genetic Disease Causative Genes and Pathogenic Genome Rearrangement" won the second prize of the National Natural Science Award (the first completer), and in 2017, he won the He Liang He Li Medical Pharmacy Award and the National Innovation Scramble Award.
Pay attention to the headline number of "Peking Union Medical College Recruitment" for more exciting information!
The source of this article is the official website of Peking Union Medical College, the official website of the Chinese Academy of Engineering, and the official website of the Chinese Academy of Sciences